The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report ...

Pharmacies like Snyders rely on reimbursements to make ends meet. When his business dispenses prescriptions, the repayment ...

Melissa Rivers recalls how quickly the Los Angeles wildfires spread, leaving her little time to gather cherished belongings ...

CVS and its top executives succeeded Tuesday in convincing Rhode Island’s top court to affirm the dismissal of allegations ...

Prescription benefit managers have been under growing scrutiny from state and federal regulators who have accused them of creating pharmacy deserts by steering consumers to their own pharmacies and ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...

Shares of CVS Health Corp. CVS inched 0.10% higher to $51.57 Tuesday, on what proved to be an all-around positive trading ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...